RedHill Biopharma Acquires Technology from University of Minnesota as Part of Ongoing RHB-104 Phase III Crohn's Program
GlobeNewswire - Thu Dec 18, 5:05AM CST
-- The acquired diagnostic technology is intended for the detection of Mycobacterium avium subspecies paratuberculosis (MAP) bacterium; Increasing evidence supports the hypothesis that Crohn's disease is caused by MAP infection in susceptible patients
RDHL: 12.22 (-0.13), DGX: 67.94 (-0.16)
RedHill commences new Phase 3 Bekinda study in U.S.
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 8:03AM CST
RDHL: 12.22 (-0.13)
RedHill Biopharma Announces First Patients Enrolled in the Phase III Study of RHB-102 (BEKINDA(TM)) for Gastroenteritis and Gastritis
GlobeNewswire - Wed Dec 17, 5:05AM CST
-- The randomized, double-blind, placebo-controlled Phase III study with RHB-102 for acute gastroenteritis and gastritis (the GUARD study) is underway in the U.S., with a planned enrollment of 320 patients
RDHL: 12.22 (-0.13)
Systemic Lupus Erythematosus - Pipeline Review, H2 2014
M2 - Thu Dec 11, 5:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/lhg87v/systemic_lupus) has announced the addition of the "Systemic Lupus Erythematosus - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Systemic Lupus Erythematosus - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - F. Hoffmann-La Roche - Biogen Idec - Amgen - Sanofi - Eli Lilly and Company - GlaxoSmithKline - MedImmune - Biotest - Ablynx - Novo Nordisk - Takeda Pharmaceutical Company - Eisai - Pfizer - UCB - Celgene Corporation - XTL Biopharmaceuticals - Merck - 4SC - Harbor Therapeutics - Immunomedics - Idera Pharmaceuticals - Karo Bio - Dynavax Technologies - Hansa Medical - Immupharma - Argos Therapeutics - MacroGenics - Kineta - Xencor - SBI Biotech - Invion Limited - Anthera Pharmaceuticals - SuppreMol - NasVax - Lycera - Genosco - RedHill Biopharma - National Pharmaceutical - Resolve Therapeutics - Lead Discovery Center - Genovax - MENTRIK Biotech - Avipep Pty - AbbVie - ImmuNext - Cellular Biomedicine Group - Medsenic - Azano Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/lh...emic_lupus
DVAX: 15.35 (+0.30), BIIB: 340.89 (+5.13), IMMU: 4.41 (+0.13), RDHL: 12.22 (-0.13), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), GSK: 42.85 (+0.11), ARGS: 9.65 (+0.34), NVO: 43.80 (+1.08), IDRA: 3.89 (+0.02), ANTH: 1.48 (unch), MRK: 57.46 (+0.25), CBMG: 12.98 (+0.19), CELGZ: 3.34 (-0.01)
RedHill submits MAA for ondansetron
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 11:38AM CST
INSY: 41.52 (+0.51), TSRO: 36.80 (+0.57), HRTX: 9.75 (+0.02), RDHL: 12.22 (-0.13), GWPH: 68.08 (+1.82), OPK: 9.63 (+0.21), GALE: 1.49 (-0.02)
RedHill Biopharma Submits BEKINDA(TM) (RHB-102) European Marketing Authorization Application for Oncology Support
GlobeNewswire - Tue Dec 09, 5:33AM CST
-- RHB-102, newly branded as BEKINDA, is a proprietary once-daily oral pill formulation of the antiemetic drug ondansetron
RDHL: 12.22 (-0.13)
RedHill Biopharma to Sponsor and Exhibit Its Ongoing Phase III Crohn's Program at the Israeli IBD Society Meeting
GlobeNewswire - Tue Dec 02, 6:00AM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"
RDHL: 12.22 (-0.13)
German regulator starts review of Rizaport MAA
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 7:43AM CST
RDHL: 12.22 (-0.13)
IntelGenx and RedHill Biopharma Announce Acceptance for Review of European Marketing Application for RIZAPORT(TM) for Migraines
GlobeNewswire - Mon Dec 01, 7:03AM CST
-- The German Federal Institute for Drugs and Medical Devices ("BfArM"
RDHL: 12.22 (-0.13), IGX.VN: 0.570 (unch)
RedHill Biopharma and IntelGenx Announce Acceptance for Review of European Marketing Application for RIZAPORT(TM) for Migraines
GlobeNewswire - Mon Dec 01, 7:00AM CST
-- The German Federal Institute for Drugs and Medical Devices (BfArM) has validated the European Marketing Authorization Application submitted for RIZAPORT (RHB-103) and initiated its formal review of the application on November 25, 2014
RDHL: 12.22 (-0.13), IGX.VN: 0.570 (unch)
Redhill Biopharma's (RDHL) CEO Dror Ben Asher on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 2:01PM CST
RDHL: 12.22 (-0.13)
FDA tags RedHill's RHB-105 a QIDP
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:02AM CST
RDHL: 12.22 (-0.13)
Redhill beats by $0.44
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:11AM CST
RDHL: 12.22 (-0.13)
FDA Grants QIDP Fast-Track Designation to RedHill Biopharma's Phase III H. pylori Drug RHB-105
GlobeNewswire - Mon Nov 10, 6:28AM CST
-- Under the FDA's Generating Antibiotic Incentives Now (GAIN) Act, the Qualified Infectious Disease Product (QIDP) designation allows for additional five years of market exclusivity in addition to existing exclusivity, Fast-Track status (an expedited development pathway) and Priority Review status (shortened review time for marketing applications)
RDHL: 12.22 (-0.13)
RedHill Biopharma Reports Results for the Third Quarter of 2014
GlobeNewswire - Mon Nov 10, 5:30AM CST
-- A strong cash position of approximately $29 million at the end of the third quarter of 2014, enabling the Company to continue to execute its R&D programs including the three ongoing Phase III studies in gastrointestinal indications: RHB-104 for Crohn's disease, RHB-105 for H. pylori infection and RHB-102 for acute gastroenteritis and gastritis
RDHL: 12.22 (-0.13)
RedHill Bio reports November 10
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 9:39AM CDT
RDHL: 12.22 (-0.13)
RedHill Biopharma to Host Third Quarter 2014 Financial Results Conference Call on November 10, 2014
GlobeNewswire - Tue Oct 28, 6:15AM CDT
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"
RDHL: 12.22 (-0.13)
RedHill Biopharma to Present at the 20th Annual BIO-Europe International Partnering Conference
GlobeNewswire - Wed Oct 22, 8:44AM CDT
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"
RDHL: 12.22 (-0.13)
This Small Cap Is Poised To Tap Multi-Billion Dollar Migraine Treatment Market
Tedra DeSue - at Seeking Alpha - Thu Oct 16, 8:14AM CDT
RDHL: 12.22 (-0.13)